|
|
Leadership Professor Frank Chisari
Professor Frank Chisari, VIRIOME’s scientific founder, has been a member of the scientific faculty at The Scripps Research Institute for more than 30 years. He serves as an advisor to the Center for Study of Hepatitis C of the Rockefeller University, The Northeast Biodefense Center, the Pew Scholars Program in Biomedical Sciences, and the University of California at San Diego Cancer Center. He has also served as a consultant to Gilead Sciences, Nucleonics, Inc., Anadys Pharmaceuticals, Globeimmune, Inc. Valeant Pharmaceuticals and Novartis Pharmaceuticals. Professor Chisari has also served as a member of the U.S.-Japan Cooperative Medical Sciences Program from 1992-98, and he was a member of the Board of Scientific Councilors of the National Institute of Allergy and Infectious Disease in 2001 and 2005. Professor Chisari has authored more than 300 publications during his distinguished scientific career. He received his medical degree from Cornell University and was a Fogarty Scholar at the Pasteur Institute. Professor Chisari is also a member of the National Academy of Sciences and the Institute of Medicine. Professor Barry Sharpless
The Nobel Prize winner, Prof. K. Barry Sharpless is the W. M. Keck Professor of Chemistry, The Scripps Research Institute, La Jolla, California. Dr. Sharpless has always looked for “useful” new chemical methods. He is best known for discovering general reactions for chiral catalysts, catalytic asymmetric epoxidation, dihydroxylation, and aminohydroxylation, for which he received the Nobel Prize in 2001. Current research focuses on click chemistry, his new synthetic stratagem for the rapid discovery of chemical function. A copper-catalyzed ‘fusion’ of azides and alkynes developed at Scripps is a near-universal best reaction for click chemistry, functioning under essentially all conditions (even in living cells) and proving to be a route to highly diverse chemical products of all types, whether polyolefins, smart materials or drugs. Dr. Sharpless graduated from Dartmouth College, received a Ph.D. from E. E. van Tamelen, Stanford University, and did a postdoc with J. P. Collman, Stanford, and at Harvard with Konrad Bloch. He served on the faculties of MIT (1970-1977), Stanford (1977-1980), MIT (1980-1990), and The Scripps Research Institute and its Skaggs Institute for Chemical Biology (1990-present). His honors and awards are too numerous to list but include the first Paul Janssen Prize for Creativity in Organic Synthesis, ISI Highly Cited Researcher beginning in 2001, the Chemical Sciences Award from the National Academy of Science in 2000, and Centenary Lectureship Medal, Royal Society of Chemistry, 1993. He is the author of hundreds of publications and is on the editorial board or advisory board of Advanced Synthesis & Catalysis,
Chirality, Current Opinion in Drug Discovery & Development, Current Drug Discovery Techniques, Enantiomer, Organic Letters, and Synlett. Dr. Linda M. Pullan, CEO
Linda Pullan has over 20 years of drug industry experience beginning in drug discovery at what is now Pfizer, becoming a project team leader at what is now AstraZeneca (contributing to the development of Seroquel the multi-billion dollar anti-psychotic. Linda then switched to licensing, and subsequently joined Amgen as head of oncology and hematology licensing, leaving to become VP of business development at Kosan Biosciences and for the last 3 years, a biotech business development consultant (www.PullanConsulting.com). She is also author of the free email newsletter on business and science of the drug industry, Pullan's Pieces. |
|